XB-628
- Generic Name
- XB-628
Exelixis Initiates Phase 1 Trial of XB628, a Novel Bispecific NK Cell Engager for Advanced Solid Tumors
• Exelixis has begun dose-escalation in a first-in-human Phase 1 trial of XB628, a first-in-class bispecific antibody targeting both NKG2A and PD-L1 in patients with recurrent advanced or metastatic solid tumors.
• XB628 represents a novel immunotherapy approach by engaging natural killer cells through dual targeting of an inhibitory receptor (NKG2A) and the immune checkpoint protein PD-L1.
• The investigational therapy was developed through a collaboration between Exelixis and Invenra, leveraging Invenra's proprietary B-Body® platform for creating multispecific antibodies with superior biophysical properties.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath